重要性是模型對已發布報導給出的 1–5 分，不是對市場的預測。
已排定事件列上的影響是公司顯著度層級（高/中由圖譜中心度與規模判定；低僅用於人工整理的次要事件），不是對波動幅度的預測。
標記為已確認的財報日期，是 Yahoo Finance 認定由公司確認的；預估表示尚未公布。未加標記的列沒有可查的出處記錄。
經濟數據發布屬於總體經濟、不歸屬任何產業，因此在任何檢視下都會保留。沒有數值的發布表示尚未公布，頁面會直說，而不是顯示為零。
涵蓋被追蹤公司的即將到來的事件；已過去的事件會歸檔，並在可得時補上結果——這些結果都經人工整理並附引用，絕不杜撰。沒有結果的歷史列會顯示「結果待定」。
閉鎖期屆滿或指數調整的列會多出一行算術——將變得可賣出的股數，或指數基金必須買進的股數，以佔流通股的比例表示——依招股說明書或指數編製方法讀出，兩個數字都在該列註明出處。它陳述的是機制，不是價格走勢。由 IPO + 180 天推算出的閉鎖期日期會一直標為預估，直到公司自己說明為止。
10月24日週六
9月22日週二
產品
Microsoft made OpenAI's GPT-6 Sol and GPT-6 Luna generally available in Microsoft Foundry alongside GPT-6 Astra, with Standard deployment for all three across all 28 Global regions and US and EU Data Zones.
September 22 5 min read GPT-6 Astra, Sol, and Luna: For production agents in Microsoft Foundry By Naomi Moneypenny , Partner Group Product Manager Listen to this post / 1x
產品
CoreWeave announced Remote Key Encryption, a security product that encrypts customer data at rest on CoreWeave using keys generated, stored and rotated in the customer's own key store, so CoreWeave only ever holds ciphertext. It will be available later this year for data on CoreWeave AI Object Storage.
If you run either the security or platform team at a large enterprise, then you've probably lived some version of this: the AI team has a model ready, the business wants it in production, and the whole thing is parked in security review because nobody can answer two questions cleanly. Who can touch it? And who holds the keys? Those questions are hard for a reason. Enterprise AI is only useful when it can leverage business-critical, often sensitive data, and the frameworks that govern that data (PCI DSS, GDPR, ISO 27001) without creating another disconnected set of controls. You're be…
合作
SGE, GE Vernova, Hitachi and Samsung C&T signed a memorandum of understanding establishing a framework for cooperation on market development and commercial opportunities for deploying the BWRX-300 small modular reactor in Central and Eastern Europe and the United Kingdom.
Skip to main content press release GE Vernova SGE, GE Vernova, Hitachi and Samsung C&T sign MoU to advance BWRX-300 fleet deployment in Europe 11 min read NEW YORK (September 22, 2026) – SGE, GE Vernova, Hitachi and Samsung C&T have signed a Memorandum of Understanding (MoU) establishing a framework for cooperation on market development and commercial opportunities for the deployment of the BWRX-300 small modular reactor in Central and Eastern Europe and the United Kingdom. The MoU was signed in New York during the Atlantic Council Nuclear Energy Policy Summit, held on the sidelines of the Uni…
監管
AWS said it is the first cloud provider approved for use by all NATO member nations to handle information at the NATO RESTRICTED level. NATO, its defense industry partners and member nations can now use approved AWS services for such workloads in any AWS Region located in a NATO member nation.
Key takeaways NATO, its defense industry partners, and all member nations can now use approved AWS services to handle NATO RESTRICTED workloads. AWS's NATO-wide approval helps allied nations fast-track their own national accreditation of AWS. AWS has 15 Regions in NATO member nations, seven of which are in mainland Europe. Amazon Web Services (AWS) announced that it is the first cloud provider to have its cloud capabilities approved for use by all North Atlantic Treaty Organization (NATO) member nations when handling information at the NATO RESTRICTED (NR) level. Benefits for global defen…
產品
At Psych Congress 2026, Lilly presented Phase 1 multiple-ascending-dose data for brenipatide, a long-acting dual GIP/GLP-1 receptor agonist that is already in Phase 3 trials for alcohol use disorder and major depressive disorder. GI-related adverse events occurred in 25% of both the brenipatide and placebo groups, and topline Phase 3 data are expected in early 2028.
SUBSCRIBE Menu SUBSCRIBE Show Search Search Query Submit Search News Drug Development Lilly presents early data supporting GLP-1/GIP candidate’s potential in depression, alcohol use disorder September 22, 2026 | 5 min read | Heather McKenzie Twitter LinkedIn Facebook Email Print iStock, Olga Strelnikova With a trillion-dollar market cap and a wildly successful GLP-1 portfolio, Eli Lilly isn’t resting on its laurels. At the Psych Congress 2026, the company presented early-stage data that could support the potential of its next-gen GLP-1 and GIP receptor agonist to treat diseases far beyond obes…
